Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process: 2022-2024

Historic Work In Process for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $7.7 million.

  • Axsome Therapeutics' Work In Process rose 56.87% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 56.87%. This contributed to the annual value of $7.7 million for FY2024, which is 24.92% down from last year.
  • Per Axsome Therapeutics' latest filing, its Work In Process stood at $7.7 million for FY2024, which was down 24.92% from $10.3 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Work In Process registered a high of $14.0 million during FY2022, and its lowest value of $7.7 million during FY2024.
  • Over the past 3 years, Axsome Therapeutics' median Work In Process value was $10.3 million (recorded in 2023), while the average stood at $10.7 million.
  • Data for Axsome Therapeutics' Work In Process shows a maximum YoY decreased of 26.34% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Work In Process (Yearly) stood at $14.0 million in 2022, then fell by 26.34% to $10.3 million in 2023, then fell by 24.92% to $7.7 million in 2024.